子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Nitric oxide-releasing molecules | US12497113 | 2009-07-02 | US08101589B2 | 2012-01-24 | Ernst V. Arnold; Blaine G. Doletski; Robert E. Raulli |
| This invention relates to compositions comprising carbon-based diazeniumdiolates that release nitric oxide (NO). The carbon-based diazeniumdiolated molecules release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated molecules, compositions comprising such molecules, methods of using such compositions, and devices employing such molecule compositions. | ||||||
| 102 | Modified surface material, method for preparing same and uses thereof | US11628205 | 2005-06-02 | US08053567B2 | 2011-11-08 | Mohamed Mehdi Chehimi; Jean Pinson; Bernadette Charleux; Christophe Bureau; Christopher Tronche; Tarik Matrab; Christian Perruchot; Eva Cabet-Deliry; Maud Save |
| The use of at least one diazonium salt bearing an initiator function, for forming an undercoat obtained by grafting a graft derived from the diazonium salt and bearing an initiator function at the surface of a conductive or semiconductive material on the undercoat, and for forming on the undercoat a polymeric layer obtained by polymerization, in particular free radical polymerization, in situ of at least one monomer, initiated from the initiator function. | ||||||
| 103 | Compounds and methods for labeling oligonucleotides | US12853741 | 2010-08-10 | US08030460B2 | 2011-10-04 | Andrei Laikhter; Joseph A. Walder; Mark Behlke; Mikhail Podyminogin; Yawfui Yong |
| A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile. | ||||||
| 104 | Method of conditioning azo pigments containing carboxylic ester groups | US12322260 | 2009-01-30 | US07999086B2 | 2011-08-16 | Jens Paetzold; Carsten Plueg; Frank Alfter |
| The invention provides a method of conditioning azo pigments containing carboxylic ester groups, using glycol monoalkyl ethers or mixtures of glycols and glycol dialkyl ether. | ||||||
| 105 | Pentacyclic anion salts or tetrazapentalene derivatives and their uses as ionic conducting materials | US10926283 | 2004-08-25 | US07906235B2 | 2011-03-15 | Christophe Michot; Michel Armand; Michel Gauthier; Yves Choquette |
| The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention includes an anionic portion combined with at least one cationic portion Mm+ in sufficient numbers to ensure overall electronic neutrality; the compound is further comprised of M as a hydroxonium, a nitrosonium NO+, an ammonium —NH4+, a metallic cation with the valence m, an organic cation with the valence m, or an organometallic cation with the valence m. The anionic load is carried by a pentacyclical nucleus of tetrazapentalene derivative bearing electroattractive substituents. The compounds can be used notably for ionic conducting materials, electronic conducting materials, colorant, and the catalysis of various chemical reactions. | ||||||
| 106 | INHIBITORS OF CATHEPSIN S | US12764772 | 2010-04-21 | US20100204200A1 | 2010-08-12 | Hong Liu; Arnab Chatterjee; David C. Tully; Phillip Alper; Badry Bursulaya; Jianhua Guo; David H. Woodmansee; Daniel Mutnick; Donald S. Karanewsky; Yun He |
| The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: wherein Q is an optionally substituted azetidinyl, pyrrolidinyl, piperidyl, and indolinyl; or Q is NR25R26; and A, R5, R6, R7, R8, R9, R25, R26 and Ar are substituents. | ||||||
| 107 | Prophylactic/therapeutic agent for cancer | US11988995 | 2005-07-22 | US20090155241A1 | 2009-06-18 | Tetsuo Mashima; Takashi Tsuruo |
| A compound or its salt that inhibits the activity of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1; a compound or its salt that inhibits the expression of a gene for the protein; an antisense polynucleotide comprising a nucleotide sequence complementary or substantially complementary to the nucleotide sequence of a polynucleotide encoding the protein or a partial peptide thereof or a part of the nucleotide sequence; an antibody against the protein; etc. are useful as preventive/therapeutic agents for cancer, apoptosis promoters for cancer cells, or the like. | ||||||
| 108 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | US11900323 | 2007-09-11 | US07524941B2 | 2009-04-28 | Jerzy Olejnik; Edyta Krzymanska-Olejnik; Sergey Mamaev; Kenneth J. Rothschild |
| The present invention relates to methods for the preparation of chemically aminoacylated tRNAs for the purpose of introduction of markers into nascent proteins. The present invention also relates to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system utilizing chemically aminoacylated tRNAs. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. | ||||||
| 109 | IONIC LIQUID, A METHOD OF SYNTHESIZING AN IONIC LIQUID, A PRECURSOR OF AN EXPLOSIVE COMPOSITION INCLUDING AT LEAST ONE IONIC LIQUID, AND A METHOD OF DESENSITIZING AN EXPLOSIVE COMPOSITION | US11735105 | 2007-04-13 | US20080251169A1 | 2008-10-16 | Steven M. Nicolich; Alexander J. Paraskos; Daniel W. Doll; Gary K. Lund; Wendy A. Balas |
| An ionic liquid is disclosed A precursor composition that comprises at least one ionic liquid and at least one energetic material is also disclosed, as is a method of synthesizing an ionic liquid and a method of desensitizing an explosive composition. | ||||||
| 110 | Cationic azo dyes with julolidine units, dyeing composition containing them, method of dyeing | US11508272 | 2006-08-23 | US07407517B2 | 2008-08-05 | Nicolas Daubresse; Andrew Greaves |
| The present disclosure relates to the use of cationic azo compounds with julolidine units as direct dyes, for the dyeing of keratin fibers, including human keratin fibers, such as the hair. The present disclosure also relates to a dyeing composition for the dyeing of keratin fibers, including human keratin fibers such as the hair, containing at least one cationic direct azo dye with julolidine units, in a suitable dyeing medium. The present disclosure also relates to a method of dyeing of keratin fibers, including human keratin fibers such as the hair, employing the dyeing composition according to the disclosure. The present disclosure also relates to cationic azo compounds with julolidine units. | ||||||
| 111 | Photocleavable DNA transfer agent | US10884530 | 2004-07-02 | US07332477B2 | 2008-02-19 | J. Kevin Cammack; Sang Van; Peng Wang |
| The present invention provides visible light sensitive and ultraviolet (UV) light sensitive composition for DNA transfer comprising acid sensitive polyacetals developed as DNA/RNA delivery agents, a photoacid generator and optionally a photosensitizer. | ||||||
| 112 | Nonpeptide insulin receptor agonists | US11167026 | 2005-06-23 | USRE39866E1 | 2007-10-02 | Richard Sportsman; Hugo O. Villar; Lawrence M Kauvar; Wayne R Spevak |
| Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula wherein each A is independently a proton-accepting substituent; each R is independently a noninterfering substituent; n is 0, 1, or 2; and each linker is independently an isostere of —NHCONH— or of —N═N— or of —NHCO—. Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities. | ||||||
| 113 | Substituted-polyaryl chromophoric compounds | US10399271 | 2001-10-17 | US07205347B2 | 2007-04-17 | Alireza Gharavi; Haythem Saadeh |
| The invention provides for novel substituted-polyaryl chromophoric compounds which desirably comprise a single diazo group, and optimally include a plurality of diazo groups. Preferably the chromophores exhibit optical nonlinear second-order properties and have unique absorption maximum and other chromophoric properties that make them useful for, among other things, multifunctional optical switches or waveguides. | ||||||
| 114 | Novel sulfonyldiazomethanes, photoacid generators, resist compositions, and patterning process | US10776159 | 2004-02-12 | US20040167322A1 | 2004-08-26 | Youichi Ohsawa; Katsuhiro Kobayashi; Yoshitaka Yanagi; Kazunori Maeda |
| A chemical amplification type resist composition comprising a specific benzenesulfonyldiazomethane containing a long-chain alkoxyl group at the 2-position on benzene ring has many advantages including improved resolution, improved focus latitude, minimized line width variation or shape degradation even on long-term PED, minimized debris left after coating, development and peeling, and improved pattern profile after development and is thus suited for microfabrication. | ||||||
| 115 | Use of copper complexes of disazo dyes for dyeing natural and synthetic material | US10451834 | 2003-06-25 | US20040054153A1 | 2004-03-18 | Adolf Kaser |
| Use of the mono-copper complex of a dye of formula (1) wherein Z1, Z2, R1, R2, R3, R4, X, n and m are as defined in the claims, and mixtures thereof with the bis-copper complex of such a dye, for dyeing natural and synthetic material. | ||||||
| 116 | Fluorene compounds containing various functional groups, polymers thereof and el element using the same | US10135728 | 2002-05-01 | US20030091859A1 | 2003-05-15 | Hyun-Nam Cho; Sung Hyun Jung; Sang Won Son |
| The present invention relates to fluorene compounds and polymers thereof, having various structures and functional groups, and capable of being used as a luminescent material for organic and polymer-based electro-luminescence (EL) element and other optical element, and to an EL element using the same as a luminescent material. | ||||||
| 117 | Metal-chelating 2,6-disubstituted pyridine compounds and their use | US759437 | 1991-09-13 | US6127529A | 2000-10-03 | Marek Kwiatkowski; Christian Sund; Jyrki Ylikoski; Veli-Matti Mukkala; Ilkka Hemmila |
| Bifuncitonal chelating pyridine compound and its use for conferring chelating properties on organic compounds. The pyridine compound has the structure ##STR1## where (i) n is an integer 1 or 2,(ii) R.sub.1, R.sub.2 and R.sub.3 represent groups that have no electrons capable of significantly delocalizing or resonating with the pyridine ring, such as hydrogen, alkyl or aralkyl having an aliphatic carbon atom next to the pyridine ring; at least two of R.sub.1, R.sub.2 and R.sub.3 being hydrogen,iii) Z an Z' represent identical or different structures, each of which comprises at least one heteroatom having a free pair of electrons as that the said at least one heteroatom together with the nitrogen atom of the pyridine ring is capable of chelating a metal ion,iv) - - - - specifies that the group X-Y is a substituent replacing a hydrogen anywhere in the parent pyridine compound, andv) X-Y represents an organic group which is inert to said chelation, and in which iX is an inert and stable bridge and Y is a functional group or a residue of an organic compounbd that has properties conferred on the compound of formula II; said group X-Y being linked to the pyridine ring of formula II via an aliphatic carbon atom attached to and acid ester, salt and chelate forms thereof involving at least one of said chelating heteroatoms. | ||||||
| 118 | Process of controlling particle size of naphthoquinone diazide esters | US995509 | 1997-12-22 | US06077942A | 2000-06-20 | Joseph E. Oberlander |
| A process for producing a naphthoquinone diazide ester of a phenolic compound that is useful in a photoresist composition, which process comprises providing a naphthoquinone diazide ester solution in an organic polar solvent; adding the resulting naphthoquinone diazide ester solution to a precipitation bath that is maintained at a temperature of from about 0.degree. C. to about -30.degree. C.; and filtering the resulting naphthoquinone diazide ester. | ||||||
| 119 | Bistriazenes as chemotherapeutic agents | US302480 | 1994-09-12 | US5808038A | 1998-09-15 | Christopher J. Michejda; Jeffrey J. Blumenstein |
| The present invention is directed to bistriazene compounds, pharmaceutical compositions containing effective anti-cancer amounts of these compounds, a method for treating cancer comprising administering to affected subjects an anti-cancer effective amount of a bistriazene compound, and the use of bistriazene compounds as crosslinking reagents applicable to the synthesis and manipulation of polymeric macromolecules. | ||||||
| 120 | Analgesic peptides from venom of grammostola spatulata and use thereof | US775476 | 1996-12-30 | US5776896A | 1998-07-07 | Richard Alexander Lampe |
| The present invention provides novel methods of treating pain comprising administering to a mammal in need of such treatment an effective analgesic amount of a peptide having the amino acid sequence of SEQ ID. NO.:1 or SEQ ID NO: 2. The invention further provides a purified peptide having the amino acid sequence of SEQ ID NO: 1. The peptides of SEQ ID NO.: 1 and SEQ ID NO.: 2 can also be used in methods for identifying compounds having analgesia-inducing activity. | ||||||
QQ群二维码
意见反馈
意见反馈